- Home
- RERE vs PHAT Comparison
RERE vs PHAT Comparison
Compare RERE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- PHAT
- Stock Information
- Founded
- RERE 2011
- PHAT 2018
- Country
- RERE China
- PHAT United States
- Employees
- RERE N/A
- PHAT N/A
- Industry
- RERE Other Specialty Stores
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- PHAT Health Care
- Exchange
- RERE Nasdaq
- PHAT Nasdaq
- Market Cap
- RERE 932.6M
- PHAT 835.7M
- IPO Year
- RERE 2021
- PHAT 2019
- Fundamental
- Price
- RERE $4.26
- PHAT $10.75
- Analyst Decision
- RERE
- PHAT Strong Buy
- Analyst Count
- RERE 0
- PHAT 5
- Target Price
- RERE N/A
- PHAT $16.40
- AVG Volume (30 Days)
- RERE 1.5M
- PHAT 1.2M
- Earning Date
- RERE 11-19-2025
- PHAT 11-06-2025
- Dividend Yield
- RERE N/A
- PHAT N/A
- EPS Growth
- RERE N/A
- PHAT N/A
- EPS
- RERE 0.12
- PHAT N/A
- Revenue
- RERE $2,588,775,650.00
- PHAT $114,039,000.00
- Revenue This Year
- RERE $30.66
- PHAT $213.11
- Revenue Next Year
- RERE $25.12
- PHAT $91.84
- P/E Ratio
- RERE $35.70
- PHAT N/A
- Revenue Growth
- RERE 27.39
- PHAT 1049.82
- 52 Week Low
- RERE $2.00
- PHAT $2.21
- 52 Week High
- RERE $4.93
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- RERE 45.42
- PHAT 42.71
- Support Level
- RERE $4.50
- PHAT $11.74
- Resistance Level
- RERE $4.78
- PHAT $12.97
- Average True Range (ATR)
- RERE 0.22
- PHAT 0.85
- MACD
- RERE -0.05
- PHAT -0.10
- Stochastic Oscillator
- RERE 15.83
- PHAT 17.92
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.